Australia markets open in 4 hours 27 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.81+0.22 (+2.56%)
As of 03:33PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 596.11M
Enterprise value 444.96M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.73
52-week change 3-23.85%
S&P500 52-week change 3-3.35%
52-week high 331.50
52-week low 37.13
50-day moving average 310.70
200-day moving average 315.47

Share statistics

Avg vol (3-month) 3942.29k
Avg vol (10-day) 31.05M
Shares outstanding 576.92M
Implied shares outstanding 6N/A
Float 873.85M
% held by insiders 13.04%
% held by institutions 130.64%
Shares short (28 Apr 2022) 48.13M
Short ratio (28 Apr 2022) 410.9
Short % of float (28 Apr 2022) 410.88%
Short % of shares outstanding (28 Apr 2022) 410.57%
Shares short (prior month 30 Mar 2022) 47.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 306 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-23.81%
Return on equity (ttm)-42.49%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-40.94M
Diluted EPS (ttm)-0.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)151.15M
Total cash per share (mrq)1.98
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)14.90
Book value per share (mrq)1.92

Cash flow statement

Operating cash flow (ttm)-26.01M
Levered free cash flow (ttm)-10.23M